Market Strategies International | Market Research and Consulting - Knowledge Center - Syndicated Studies

Syndicated Studies

MSImage Oncology & Hematology Study

Market Strategies' sixth annual MSImage Oncology & Hematology Study identifies the pharmaceutical/biopharmaceutical companies that have the best overall image.

The study was conducted with 465 physicians, 100 oncology nurses and 100 oncology practice managers who evaluated more than 30 attributes that encompass sales professionals, corporate equity and R&D attributes. These ratings are used to determine which measures drive a pharmaceutical/biopharmaceutical company’s image and performance.

The MSImage Oncology & Hematology Study helps such companies better understand their strengths and weaknesses among key stakeholders. It can be used by companies to effectively drive performance measures, influencing decision makers to engage in more positive behaviors toward high performing companies. It also can be used to develop strategies for sales reps to become more effective in the present and future.

This emphasis on image leadership can lead to increased customer loyalty, actual and future purchase intentions, peer recommendations and a general willingness to participate in pharmaceutical/biopharmaceutical programs and clinical trials and to see more sales reps from that company.

Benefits to purchasing the study include:

Detailed results for all companies with insights as to why top-rated companies like Genentech, Novartis, Celgene, Sanofi-Aventis, AstraZeneca, Amgen, and Eli Lilly/ImClone lead the way.
Identification of the relative impacts of drivers on corporate image and key attributes.
The ability to benchmark against competitors on attribute performance and the comparison of relative positions companies have on each attribute.
Detailed benchmarking to past studies.

With your subscription to the 2011 MSImage Oncology & Hematology Study you will receive:

A detailed presentation report complete with strategic insights and recommendations:
- All Company 2011 master card which includes the 2011 scores on key measures, statistical significance between companies on these measures, and ranks for all companies included in this year’s study.
- Competitive Set 2011 master card which includes the 2011 scores and statistical significance between companies for your competitive set on key measures.
- Competitive Set Trend master card which includes the scores for your competitive set for 2009, 2010, and 2011 on key measures. Color coding is used to indicate significant differences between 2010 and 2011 data.
On site customized presentation.

For additional information on the MSImage Oncology and Hematology study, as well as other MSImage studies such as the ASCO syndicated study, please contact: Oncology@marketstrategies.com or corpmktg@marketstrategies.com .